Cancer of the Prostate: Molecular Genetics
213
Giroldi, L.A.,
Bringuier, P.P.,
Schalken, J.A.
(1994)
Defective
E-cadherin
function
in
urological cancers: clinical implications and
molecular mechanisms,
Invasion Metastasis
14
, 71–81.
Gottlieb, B., Lehvaslaiho, H., Beitel, L.H., et al.
(1998) The androgen receptor gene mutations
database,
Nucleic Acids Res.
26
, 234–238.
Graff, J.R., Herman, J.G., Lapidus, R.G., et al.
(1995) E-cadherin expression is silenced by
DNA
hypermethylation
in
human
breast
and prostate carcinomas,
Cancer Res.
55
,
5195–5199.
Gray, I.C., Phillips, S.M., Lee, S.J., et al. (1995)
Loss of the chromosomal region 10q23-24 in
prostate cancer,
Cancer Res.
55
, 4800–4803.
Grignon, D.J.,
Caplan, R.,
Sarkar, F.H.,
et al.
(1997) p53 status and prognosis of locally
advanced prostatic adenocarcinoma: a study
based on RTOG 8610,
J. Natl. Cancer Inst.
89
,
158–165.
Gu, K., Mes Masson, A.M., Gauthier, J., Saad, F.
(1996) Overexpression of her-2/neu in human
prostate cancer and benign hyperplasia,
Cancer
Lett.
99
, 185–189.
Gu, K., Mes-Masson, A.M., Gauthier, J., Saad, F.
(1998) Analysis of the p16 tumor suppressor
gene
in
early-stage
prostate
cancer,
Mol.
Carcinog.
21
, 164–170.
Gumerlock, P.H.,
Poonamallee, U.R.,
Mey-
ers, F.J., de Vere White, R.W. (1991) Activated
ras alleles in human carcinoma of the prostate
are rare,
Cancer Res.
51
, 1632–1637.
Halvorsen, O.J.,
Haukaas, S.A.,
Akslen, L.A.
(2003) Combined Loss of PTEN and p27
expression
is
associated
with
tumor
cell
proliferation by Ki-67 and increased risk of
recurrent disease in localized prostate cancer,
Clin. Cancer Res.
9
(4), 1474–1479.
Hamdy, S.M., Aprikian, A.G., Begin, L.R., et al.
(1994) ras p21 overexpression is a late event in
prostate cancer,
Int. J. Oncol.
4
, 627–631.
Harden, S.V.,
Guo, Z.,
Epstein, J.I.,
Sidran-
sky, D. (2003) Quantitative GSTP1 methy-
lation clearly distinguishes benign prostatic
tissue and limited prostate adenocarcinoma,
J.
Urol.
169
(3), 1138–1142.
Hardy, D.O., Scher, H.I., Bogenreider, T., et al.
(1996) Androgen receptor CAG repeat lengths
in prostate cancer: correlation with age of
onset,
J. Clin. Endocrinol. Metab.
81
(12),
4400–4405.
Heidenberg, H.B.,
Sesterhenn, I.A.,
Gaddi-
pati, J.P., et al. (1995) Alteration of the tumor
suppressor gene p53 in a high fraction of hor-
mone refractory prostate cancer,
J. Urol.
154
,
414–421.
Hsieh, J.T.,
Luo, W.,
Song, W.,
et al.
(1995)
Tumor suppressive role of an androgen-
regulated epithelial cell adhesion molecule
(CCAM) in prostate carcinoma cell revealed
by sense and antisense approaches,
Cancer
Res.
55
, 190–197.
Huss, W.J., Barrios, R.J., Foster, B.A., Green-
berg, N.M. (2003) Differential expression of
speci±c FGF ligand and receptor isoforms
during angiogenesis associated with prostate
cancer progression,
Prostate
54
(1), 8–16.
Irvine, R.A., Yu, M.C., Ross, R.K., Coetzee, G.A.
(1995) The CAG and GGC microsatellites of
the androgen receptor gene are in linkage
disequilibrium in men with prostate cancer,
Cancer Res.
55
, 1937–1940.
Isaacs, W.B.,
Bova, G.S.,
Morton, R.A.,
et al.
(1994) Molecular biology of prostate cancer,
Semin. Oncol.
21
, 514–521.
Ittmann, M.M., Wieczorek, R. (1996) Alterations
of
the
retinoblastoma
gene
in
clinically
localized, stage B prostate adenocarcinomas,
Hum. Pathol.
27
, 28–34.
Ivanovic, V., Melman, A., David-Joseph, B., et al.
(1995) Elevated plasma levels of TGF-
α
1in
patients with invasive prostate cancer,
Nat.
Med.
1
, 282–284.
Jarrard, D.F.,
Bova, G.S.,
Ewing, C.M.,
et al.
(1997) Deletional, mutational, and methy-
lation analyses of CDKN2 (p16/MTS1) in
primary metastatic prostate cancer,
Genes
Chromosomes Cancer
19
, 90–96.
Jarrard, D.F.,
Bussemakers, M.J.,
Bova, G.S.,
Isaacs, W.B.
(1995)
Regional
loss
of
imprinting of the insulin-like growth factor II
gene occurs in human prostate tissues,
Clin.
Cancer Res.
1
, 1471–1478.
Jenster, G. (1999) The role of the androgen
receptor in the development and progression
of prostate cancer,
Semin. Oncol.
26
, 407–421.
Joos, S.,
Bergerheim, U.S.R.,
Pan, Y.,
et al.
(1995) Mapping of chromosomal gains and
losses
in prostate
cancer
by comparative
genomic hybridization,
Genes Chromosomes
Cancer
14
, 267–276.
Kamradt, J.,
Drosse, C.,
Kalkbrenner, S.,
Ro-
hde, V., Lensch, R., Lehmann, J., Fixemer, T.,
Bonkhoff, H., Stoeckle, M., Wullich, B. (2003)
Telomerase activity and telomerase subunit
gene expression levels are not related in
prostate cancer: a real-time quanti±cation and
previous page 887 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online next page 889 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online Home Toggle text on/off